Results 71 to 80 of about 42,544 (264)

Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.

open access: yesJournal of Hepatology, 2018
BACKGROUND & AIMS To eliminate hepatitis B virus (HBV) infection, it is essential to scale up antiviral treatment through decentralized services. However, access to the conventional tools to assess treatment eligibility (liver biopsy/Fibroscan®/HBV DNA ...
Y. Shimakawa   +23 more
semanticscholar   +1 more source

The multiple logistic regression analysis for variables between HBeAg-positive and HBeAg-negative. [PDF]

open access: yes, 2015
Abbreviations: VL = viral load, WT = nodal width, CLD = chronic liver parenchymal disease, LC = liver cirrhosis.The multiple logistic regression analysis for variables between HBeAg-positive and HBeAg-negative.
Kun-Ming Chung (523221)   +9 more
core   +1 more source

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients

open access: yesBMC Gastroenterology, 2023
Abstract Background Previous studies have indicated that HBV pregenome RNA (HBV pgRNA) could predict HBeAg seroconversion among the chronic hapatitis B (CHB) patients treated with pegylated interferon (Peg-IFN) or nucleos(t)ide analogues (NAs).
Guangjun Song   +6 more
openaire   +3 more sources

Human biomarker navigator

open access: yesiMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

Mutagenesis analysis of HBeAg biogenesis. [PDF]

open access: yes, 2021
(A to D). HepG2 cells were transfected with pXF3H-p25HA derived plasmid expressing WT or mutant p25HA with the indicated single or double amino acid residue substitution and harvested at 48 h post transfection.
Hui Liu (33624)   +5 more
core   +1 more source

A new model mimicking persistent HBV e antigen-negative infection using covalently closed circular DNA in immunocompetent mice. [PDF]

open access: yesPLoS ONE, 2017
Despite the availability of an effective vaccine, hepatitis B virus (HBV) infection remains a major health problem. HBV e antigen (HBeAg)-negative strains have become prevalent.
Lei Wang   +7 more
doaj   +1 more source

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

open access: yesiNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu   +5 more
wiley   +1 more source

Spontaneous and 3-, 4-, and 5-year NA treatment-induced HBeAg seroconversion in HBeAg-positive CHB patients. [PDF]

open access: yes, 2017
Spontaneous and 3-, 4-, and 5-year NA treatment-induced HBeAg seroconversion in HBeAg-positive CHB patients.
Lin Cao (294505)   +3 more
core   +1 more source

A survey of the frequency of HBsAg+ status in pregnant women attending health centers in Ahwaz

open access: yesPayesh, 2004
Objective(s): To estimate a frequency of HBsAg prevalence by a simple sampling method on 120 pregnant women attending health centers in Ahwaz city between March and December 1998.
Mohammad jaffari R   +3 more
doaj  

Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection

open access: yesVaccines, 2021
During the natural course of chronic hepatitis B virus (HBV) infection, the hepatitis B e antigen (HBeAg) is typically lost, while the direct transmission of HBeAg-negative HBV may result in fulminant hepatitis B.
Anna D. Kosinska   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy